Leerink Partnrs Has Positive Outlook of COGT Q2 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT) – Analysts at Leerink Partnrs raised their Q2 2025 earnings per share (EPS) estimates for shares of Cogent Biosciences in a report released on Wednesday, May 7th. Leerink Partnrs analyst A. Berens now anticipates that the technology company will post earnings per share of ($0.63) for the quarter, up from their previous forecast of ($0.64). The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Cogent Biosciences’ Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.57) EPS and FY2027 earnings at $1.13 EPS.

Several other analysts have also recently weighed in on COGT. Piper Sandler raised Cogent Biosciences to a “strong-buy” rating in a report on Friday, March 7th. HC Wainwright decreased their price objective on Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. Wedbush reissued a “neutral” rating and set a $11.00 price objective on shares of Cogent Biosciences in a report on Tuesday, February 25th. Robert W. Baird decreased their price objective on Cogent Biosciences from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. Finally, Scotiabank began coverage on Cogent Biosciences in a report on Friday, March 7th. They set a “sector outperform” rating and a $17.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.29.

Cogent Biosciences Stock Down 2.7%

NASDAQ:COGT opened at $4.99 on Monday. The business’s 50-day moving average price is $5.55 and its two-hundred day moving average price is $7.64. Cogent Biosciences has a twelve month low of $3.72 and a twelve month high of $12.61. The stock has a market cap of $568.14 million, a P/E ratio of -2.01 and a beta of 1.91.

Cogent Biosciences (NASDAQ:COGT) last released its quarterly earnings results on Tuesday, May 6th. The technology company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.04.

Hedge Funds Weigh In On Cogent Biosciences

Large investors have recently bought and sold shares of the stock. CWM LLC increased its stake in Cogent Biosciences by 11,869.9% in the 1st quarter. CWM LLC now owns 8,738 shares of the technology company’s stock worth $52,000 after purchasing an additional 8,665 shares during the period. Schonfeld Strategic Advisors LLC purchased a new position in Cogent Biosciences in the 4th quarter worth approximately $78,000. Hsbc Holdings PLC purchased a new position in Cogent Biosciences in the 4th quarter worth approximately $81,000. KLP Kapitalforvaltning AS purchased a new position in Cogent Biosciences in the 4th quarter worth approximately $88,000. Finally, E Fund Management Co. Ltd. purchased a new position in Cogent Biosciences in the 4th quarter worth approximately $89,000.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.